Thread by @WHO

WHO recommends two new medicines for #COVID19, providing yet more options for treating the disease bit.ly/3flUftt

Baricitinib, a drug used to treat rheumatoid arthritis, is strongly recommended for patients with severe or critical #COVID19.
WHO recommends that it is given with corticosteroids bit.ly/3flUftt

https://twitter.com/who/status/1481949672419831810

WHO has also conditionally recommended the use of sotrovimab for treating mild or moderate #COVID19 in patients who are at high risk of hospitalization: patients who are older, immunocompromised, with underlying conditions & those unvaccinated bit.ly/3flUftt

https://twitter.com/who/status/1481949672419831810

Sotrovimab is a monoclonal antibody drug. Studies are ongoing but early laboratory studies indicate that it continues to work against the #COVID19 Omicron variant bit.ly/3flUftt

https://twitter.com/who/status/1481950881801289729

The panel of experts developing the guidelines also looked at two other drugs for severe & critical #COVID19: ruxolitinib and tofacitinib.
Given their uncertain effects, WHO made a conditional recommendation against their use bit.ly/3flUftt

https://twitter.com/who/status/1481949672419831810

Today’s recommendations - the eighth update of WHO’s living guidelines on therapeutics and #COVID19, are based on evidence from seven trials involving over 4,000 patients with non-severe, severe, and critical COVID-19 bit.ly/3flUftt

https://twitter.com/who/status/1481949672419831810

WHO and @ACTAccelerator partners are in discussions with manufacturers to secure global supply capacity and equitable & sustainable access to the newly recommended therapeutics. They are also looking to expand licensing scope to make the products more affordable.

https://twitter.com/who/status/1481949672419831810